Although there have been approved drugs targeted at hormone receptors, including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) [1], chemotherapy remains a routine treatment for breast cancer, particularly for triple-negative breast cancer (TNBC), which lacks major effective targets [2]. This evidence concerns the gene PGR and breast cancer.